违规提示

请您遵循相关法律法规,避免再次出现类似问题

如有任何疑问,请联系support@tmtpost.com

关闭
0

PEAR Therapeutics 认领应用

发布时间:1970-01-01 ・医疗健康

PEAR creates, develops, and commercializes prescription digital therapeutics and drug/software combinations to treat disease.

负责人:

成为钛媒体专业用户,即可查看联系方式




产品介绍

About Prescription Digital Therapeutics
Prescription digital therapeutics are clinically validated, FDA-cleared software applications that demonstrate safety and efficacy in randomized clinical trials to improve patient outcomes. They are designed to enhance clinical outcomes, and where clinically relevant may be combined with current treatment regimens including approved drug or device therapies. Prescription digital therapeutics usually include patient-facing applications, clinical assessment and outcomes tracking, clinician monitoring dashboards and HIPAA-compliant data storage.

About Pear Therapeutics
Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics. The company integrates clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear’s lead product, reSET®, is an FDA-cleared 12-week interval prescription therapy for Substance Use Disorder (SUD) to be used as an adjunct to standard, outpatient treatment. Pear’s product development pipeline includes reSET-O™ for opioid use disorder (OUD) and additional prescription digital therapeutics in schizophrenia (Thrive™), combat post-traumatic stress disorder (reCALL™), general anxiety disorder (reVIVE™), pain, major depressive disorder, and insomnia. See our Product Pipeline for details.

产品形态:

产品链接:

分享到:

创业故事

该产品还没有被报道,查看其他被报道产品

评论(0

对该产品发表评论

 

Oh! no

您是否确认要删除该条评论吗?

分享到微信朋友圈

注册邮箱未验证

我们已向下方邮箱发送了验证邮件,请查收并按提示验证您的邮箱。

如果您没有收到邮件,请留意垃圾邮件箱。

更换邮箱

您当前使用的邮箱可能无法接收验证邮件,建议您更换邮箱

账号合并

经检测,你是“钛媒体”和“商业价值”的注册用户。现在,我们对两个产品因进行整合,需要您选择一个账号用来登录。无论您选择哪个账号,两个账号的原有信息都会合并在一起。对于给您造成的不便,我们深感歉意。